Infrarenal by Choice



GORE[®] EXCLUDER[®] AAA Endoprosthesis

- Most studied* EVAR device
- EVAR market leader
- > 350,000+ patients treated⁺
- Over 20 years of experience
- Low rates of:[‡]
 - Migration
 - Type IA endoleak
 - Reintervention
 - Limb occlusion
 - Renal complications

Proven performance. Proven outcomes.

The most-studied* EVAR device delivers durable outcomes for your patients.





† Based on the number of Trunk-Ipsilateral Legs distributed.

GREAT. n = 3,274. To calculate the overall event rates from procedure through end of study period, all subjects who could have had events, regardless of length of follow-up, were included. For outcome data, GREAT only collects site reported serious adverse events. Therefore, all reported endoleaks are defined as serious and require reintervention.

§ One peri-procedural migration reported. Zero migrations reported during follow-up through 5 years.

Il Inclusion for renal complication rate: Subjects with renal complication were identified with MedDRA code. Of those identified with MedDRA code as having a renal complication, only those who showed the SAE occurring within 75 days of the procedure AND were reported by the site/physician as being related to the device or procedure were included in the renal complication rate.





The GORE® C3® Delivery System is repositionable to obtain optimal seal

- A unique delivery system provides the ability to reconstrain the proximal end of the device and reposition for ideal placement
- More opportunities to maximize infrarenal seal



Data from GREAT:^{*} 400 Patients, 13 EU sites, August 2010–December 2012

48.1% Physicians used repositioning

79% Optimized position to renal arteries **20%** Contralateral gate cannulation

* GREAT. n = 3,274. To calculate the overall event rates from procedure through end of study period, all subjects who could have had events, regardless of length of follow-up, were included. For outcome data, GREAT only collects site reported serious adverse events. Therefore, all reported endoleaks are defined as serious and require reintervention.

INDICATIONS FOR USE: Trunk-Ipsilateral Leg Endoprosthesis and Contralateral Leg Endoprosthesis Components. The GORE® EXCLUDER® AAA Endoprosthesis is intended to exclude the aneurysm from the blood circulation in patients diagnosed with infrarenal abdominal aortic aneurysm (AAA) disease and who have appropriate anatomy as described below: Adequate iliac / femoral access; Infrarenal aortic neck treatment diameter range of 19–32 mm and a minimum aortic neck length of 15 mm; Proximal aortic neck angulation < 60°; Iliac artery treatment diameter range of 8–25 mm and iliac distal vessel seal zone length of at least 10 mm. Aortic Extender Endoprosthesis and Iliac Extender Endoprosthesis Components. The Aortic and Iliac Extender Endoprostheses are intended to be used after deployment of the GORE® EXCLUDER® AAA Endoprosthesis. These extensions are intended to be used when additional length and / or sealing for aneurysmal exclusion is desired. CONTRAINDICATIONS: The GORE® EXCLUDER® AAA Endoprosthesis is contraindicated in patients with known sensitivities or allergies to the device materials and patients with a systemic infection who may be at increased risk of endovascular graft infection. Refer to *Instructions for Use* at goremedical.com for a complete description of all warnings, precautions and adverse events. ¹/₄ con₄

Products listed may not be available in all markets.

GORE, C3, EXCLUDER and designs are trademarks of W. L. Gore & Associates. © 2017, 2019 W. L. Gore & Associates, Inc. AW1847-EN2 OCTOBER 2019



W. L. GORE & ASSOCIATES, INC. Flagstaff, AZ 86004

+65.67332882 (Asia Pacific) 00800.6334.4673 (Europe) 800.437.8181 (United States) 928.779.2771 (United States)

goremedical.com